<!--#if expr="$title" --> <!--#echo var="title" --> <!--#else --> HIV Drug Resistance Database <!--#endif -->
Stanford University HIV Drug Resistance Database - A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance.

Isolate Data

Patient Isolate Region Year Species Subtype Source Clone Method
JF08 JF08-12w U.S. 1998 HIV1 B Plasma None

Treatment History
Order Regimen Weeks
1 IDV 72
2 SQV 24
3 AZT 104
4 DDI 32
5 DDC 8
6 D4T 16
7 3TC 44
8 ABC+APV 6

RT Sequence
NRTIMajorDRMs NRTIMinorDRMs NNRTIMajorDRMs NNRTIMinorDRMs Polys UnusualMuts
M41L, K70R, L74I, M184V, T215F D67G, K219Q     K43Q, K64R, T69N, V118I, F171Y, G196N, T200I, I202V, E204Q, Q207E, R211K, F214L, L228LH, V245T  
>JF08-12w| codons 24-260
WPLTEEKIKALVEICTELEQEGKISKIGPENPYNTPVFAIRKKGSNRWRKIVDFRELNKR
TQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSIPLDKDFRKYTAFTIPSINNETPGIR
YQYNVLPQGWKGSPAIFQSSMTKILEPYRKQNPDIVIYQYVDDLYVGSDLEINQHRIKVE
QLREHLLKWGLFTPDQKHQKEPPFHWMGYELHPDKWTVQPITLPEKDSWTVNDIQKL

Protease Sequence
PIMajorDRMs PIMinorDRMs Polys UnusualMuts
I54V, V82T, L90M   L10I, I15V, E35D, N37E, K45R, L63P, A71V, I93L, C95F  
>JF08-12w| codons 1-99
PQITLWQRPIVTIKVGGQLKEALLDTGADDTVLEDMELPGRWKPRMIGGIGGFVKVRQYD
QIPIEICGHKVIGTVLVGPTPTNIIGRNLMTQLGFTLNF

References
Author Title Citation
Falloon, J Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis, 2000
Gonzales, MJ Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS, 2003
Gonzales, MJ Protease and reverse transcriptase mutation patterns in HIV-1 isolates from heavily treated persons: Comparison of isolates from northern California with isolates from other regions. ARHR, 2003
Rhee, SY HIV-1 protease and reverse transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis, 2005